MINERALYS THERAPEUTICS INC. - COMMON STOCK

Mineralys Therapeutics Announces $120 Million Private Placement Financing

08 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

29 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

04 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

21 Dec 2023 16:05:03 By Nasdaq GlobeNewswire

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

11 Nov 2023 11:30:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in Three Upcoming Conferences

09 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 16:05:02 By Nasdaq GlobeNewswire

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

02 Nov 2023 10:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

31 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

13 Oct 2023 16:10:31 By Nasdaq GlobeNewswire

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

14 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

10 Sep 2023 07:47:12 By Nasdaq GlobeNewswire

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

10 Sep 2023 07:45:36 By Nasdaq GlobeNewswire

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

05 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023

29 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

31 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

17 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

31 May 2023 08:00:00 By Nasdaq GlobeNewswire